Surge in geriatric population and growing use of immunoglobulins in various therapeutic areas to drive global plasma fractionation market
According to TechSci Research report, “Global Plasma Fractionation Market By Product (Coagulation Factors, Immunoglobins, Protease Inhibitor. Anticoagulants, Albumin), By Method (Cohn Cold Fractioning Process, Chromatography, Cryoprecipitation, Others), By Plasma Source (Blood Test, Plasmapheresis), By Test (NAT-testing, ELISA, Screening Test), By Donor (Recovered Plasma, Source Plasma), By Application (Neurology, Immunology, Hematology, Others), By End-User (Hospitals and Clinics, Clinical Research Laboratories, Others), By Region, Competition, Forecast & Opportunities, 2025”, the market is expected to register significant growth owing to surging plasma collection with increase in number of plasma collection centers and increasing use of alpha-1-antitrypsin. Furthermore, growing geriatric population across the globe, which is susceptible to various rare diseases that require the use of plasma derivatives, is also a major factor behind the growth of global plasma fractionation market. Moreover, growing use of immunoglobulins in various therapeutic areas is also fueling the growth of the plasma fractionation market.
Additionally, increasing incidences of blood and immune disorders among individuals along with increasing off-label usage of critical plasma products such as albumins, and immunoglobulin are some other major factors expected to boost the growth of global plasma fractionation market in coming years. Increasing incidences and prevalence of chronic diseases around the globe and rising expenditure on advanced healthcare are some other factors responsible for the rising demand of plasma fractionation. Also, there are governments encouraging and creating awareness and availability of plasma-derived medicine products for therapeutic usage, which is acting as a positive factor for the market growth.
However, there are some factors restricting the growth of global plasma fractionation market. The high cost of plasma products might limit the demand for plasma fractionation. Also, limited reimbursements and increasing usage of recombinant proteins and products acting as a substitute for the plasma products might also hamper the overall growth of global plasma fractionation market.
Browse XX market data Tables and XX Figures spread through XXX Pages and an in-depth TOC on “Global Plasma Fractionation Market”
The global plasma fractionation market is segmented based on product, method, plasma source, test, donor, application, end-user and region. Based on product, the market is segmented into coagulation factors, immunoglobins, protease inhibitor, anticoagulants and albumin. The coagulation factors segment is further divided into factor VIII, factor IX, prothrombin, fibrinogen and others. Moreover, the protease inhibitor segment is divided into Alpha-1-Antitrypsin and C1-inhibitor. Among the products, the immunoglobins segment dominates the global plasma fractionation market owing to wide usage of immunoglobulin in various disorders such as primary and secondary immune deficiencies, autoimmune diseases, and inflammatory diseases. Also, surge in research related to immunology across the globe is another factor which is expected to drive the demand for immunoglobulin in the coming years.
Based on application, the global plasma fractionation market is segmented into neurology, immunology, hematology and others. Among them, the neurology segment is expected to dominate the market during the forecast period due to the surge in the neurological disorders that require plasma fractionation products for treatment. Further, increase in the adoption of plasma fractionation products in the field of neurology is driving the growth of this segment in plasma fractionation market.
Major players operating in the global plasma fractionation market include Grifols, Baxter, CSL Behring, Bio Products Laboratory, Biotest AG, China Biologic Products, Benesis Corporation, Kedrion S.p.A, Octapharma, Shire, LFB, Sanquin, GC Pharma (Green Cross Corporation), Takeda Pharmaceutical, Hualan Bio, Eli Lily, Roche, Bayer, Becton Dickinson and Intas Pharmaceutical. The market players have adopted various strategies like collaboration, product launch, partnership, and acquisition for garnering maximum market share.
Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=5091
Customers can also request for 10% free customization on this report.
“Increasing research and development activities in plasma fractionation is leading to its wide application various treatments. The presence of improvised and advanced plasma fractionation facilities and centers around the world is also boosting the market growth. However, the companies need to focus on brining cost-effective and innovative methods to become a leading player in global plasma fractionation market,” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.
“Global Plasma Fractionation Market By Product (Coagulation Factors, Immunoglobins, Protease Inhibitor. Anticoagulants, Albumin), By Method (Cohn Cold Fractioning Process, Chromatography, Cryoprecipitation, Others), By Plasma Source (Blood Test, Plasmapheresis), By Test (NAT-testing, ELISA, Screening Test), By Donor (Recovered Plasma, Source Plasma), By Application (Neurology, Immunology, Hematology, Others), By End-User (Hospitals and Clinics, Clinical Research Laboratories, Others), By Region, Competition, Forecast & Opportunities, 2025” has evaluated the future growth potential of global plasma fractionation market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges and opportunities in global plasma fractionation market.
Mr. Ken Mathews
708 Third Avenue,
New York – 10017